Loss of heterozygosity of key tumor suppressor genes in advanced renal cancer patients treated with nivolumab

Melissa Bersanelli; Letizia Gnetti; Cinzia Azzoni; Lorena Bottarelli; Nicola Sverzellati; Nicoletta Campanini; Elena Varotti; Michele Corrado; Raffaele Parziale; Elena Rapacchi; Giuseppe Caruso; Francesco Leonardi; Enrico Maria Silini; Sebastiano Buti

doi:10.2217/imt-2017-0160

Loss of heterozygosity of key tumor suppressor genes in advanced renal cancer patients treated with nivolumab

Melissa Bersanelli, Letizia Gnetti, Cinzia Azzoni, Lorena Bottarelli, Nicola Sverzellati, Nicoletta Campanini, Elena Varotti, Michele Corrado, Raffaele Parziale, Elena Rapacchi, Giuseppe Caruso, Francesco Leonardi, Enrico Maria Silini, Sebastiano Buti

Azienda Ospedaliero - Universitaria di Parma

Risultato della ricerca: Contributo in rivista › Articolo in rivista

1 Citazioni (Scopus)

Abstract

Aim: We studied the possible clinical significance of loss of heterozygosity (LOH) at key tumor suppressor genes loci in advanced renal cancer patients treated with nivolumab. Methods: LOH study was performed on 3p14.2 (FHIT gene); 3p21.3-21.2; 9p21 (BDMF gene); 9p22 (SH3GL2 gene). Results: Of 12 patients, 8 (67%) had LOH. The most affected gene was FHIT. All five patients with LOH at FHIT locus had good outcome, mean progression free survival of 6.8 months. The patients LOH negative at FHIT locus had mean progression free survival of 4 months, 67% were treatment refractory. Overall, 75% of patients with LOH of at least one gene had benefit; 75% of LOH negative cases were refractory. Conclusion: LOH at key tumor suppressor genes should be further investigated as predictive for immunotherapy.

Lingua originale	English
pagine (da-a)	743-752
Numero di pagine	10
Rivista	Immunotherapy
Volume	10
DOI	https://doi.org/10.2217/imt-2017-0160
Stato di pubblicazione	Pubblicato - 2018

Keywords

FHIT
loss of heterozygosity
renal cell carcinoma

OSS delle Nazioni Unite

Questo processo contribuisce al raggiungimento dei seguenti obiettivi di sviluppo sostenibile

Accesso al documento

10.2217/imt-2017-0160

Altri file e collegamenti

Link a IRIS PubliCatt

Cita questo

Bersanelli, M., Gnetti, L., Azzoni, C., Bottarelli, L., Sverzellati, N., Campanini, N., Varotti, E., Corrado, M., Parziale, R., Rapacchi, E., Caruso, G., Leonardi, F., Silini, E. M., & Buti, S. (2018). Loss of heterozygosity of key tumor suppressor genes in advanced renal cancer patients treated with nivolumab. Immunotherapy, 10, 743-752. https://doi.org/10.2217/imt-2017-0160

@article{a198d1af980e4f8eb2b7151b600de027,

title = "Loss of heterozygosity of key tumor suppressor genes in advanced renal cancer patients treated with nivolumab",

abstract = "Aim: We studied the possible clinical significance of loss of heterozygosity (LOH) at key tumor suppressor genes loci in advanced renal cancer patients treated with nivolumab. Methods: LOH study was performed on 3p14.2 (FHIT gene); 3p21.3-21.2; 9p21 (BDMF gene); 9p22 (SH3GL2 gene). Results: Of 12 patients, 8 (67%) had LOH. The most affected gene was FHIT. All five patients with LOH at FHIT locus had good outcome, mean progression free survival of 6.8 months. The patients LOH negative at FHIT locus had mean progression free survival of 4 months, 67% were treatment refractory. Overall, 75% of patients with LOH of at least one gene had benefit; 75% of LOH negative cases were refractory. Conclusion: LOH at key tumor suppressor genes should be further investigated as predictive for immunotherapy.",

keywords = "FHIT, loss of heterozygosity, renal cell carcinoma, FHIT, loss of heterozygosity, renal cell carcinoma",

author = "Melissa Bersanelli and Letizia Gnetti and Cinzia Azzoni and Lorena Bottarelli and Nicola Sverzellati and Nicoletta Campanini and Elena Varotti and Michele Corrado and Raffaele Parziale and Elena Rapacchi and Giuseppe Caruso and Francesco Leonardi and Silini, {Enrico Maria} and Sebastiano Buti",

year = "2018",

doi = "10.2217/imt-2017-0160",

language = "English",

volume = "10",

pages = "743--752",

journal = "Immunotherapy",

issn = "1750-743X",

publisher = "Taylor and Francis Ltd.",

}

Bersanelli, M, Gnetti, L, Azzoni, C, Bottarelli, L, Sverzellati, N, Campanini, N, Varotti, E, Corrado, M, Parziale, R, Rapacchi, E, Caruso, G, Leonardi, F, Silini, EM & Buti, S 2018, 'Loss of heterozygosity of key tumor suppressor genes in advanced renal cancer patients treated with nivolumab', Immunotherapy, vol. 10, pagg. 743-752. https://doi.org/10.2217/imt-2017-0160

TY - JOUR

T1 - Loss of heterozygosity of key tumor suppressor genes in advanced renal cancer patients treated with nivolumab

AU - Bersanelli, Melissa

AU - Gnetti, Letizia

AU - Azzoni, Cinzia

AU - Bottarelli, Lorena

AU - Sverzellati, Nicola

AU - Campanini, Nicoletta

AU - Varotti, Elena

AU - Corrado, Michele

AU - Parziale, Raffaele

AU - Rapacchi, Elena

AU - Caruso, Giuseppe

AU - Leonardi, Francesco

AU - Silini, Enrico Maria

AU - Buti, Sebastiano

PY - 2018

Y1 - 2018

N2 - Aim: We studied the possible clinical significance of loss of heterozygosity (LOH) at key tumor suppressor genes loci in advanced renal cancer patients treated with nivolumab. Methods: LOH study was performed on 3p14.2 (FHIT gene); 3p21.3-21.2; 9p21 (BDMF gene); 9p22 (SH3GL2 gene). Results: Of 12 patients, 8 (67%) had LOH. The most affected gene was FHIT. All five patients with LOH at FHIT locus had good outcome, mean progression free survival of 6.8 months. The patients LOH negative at FHIT locus had mean progression free survival of 4 months, 67% were treatment refractory. Overall, 75% of patients with LOH of at least one gene had benefit; 75% of LOH negative cases were refractory. Conclusion: LOH at key tumor suppressor genes should be further investigated as predictive for immunotherapy.

AB - Aim: We studied the possible clinical significance of loss of heterozygosity (LOH) at key tumor suppressor genes loci in advanced renal cancer patients treated with nivolumab. Methods: LOH study was performed on 3p14.2 (FHIT gene); 3p21.3-21.2; 9p21 (BDMF gene); 9p22 (SH3GL2 gene). Results: Of 12 patients, 8 (67%) had LOH. The most affected gene was FHIT. All five patients with LOH at FHIT locus had good outcome, mean progression free survival of 6.8 months. The patients LOH negative at FHIT locus had mean progression free survival of 4 months, 67% were treatment refractory. Overall, 75% of patients with LOH of at least one gene had benefit; 75% of LOH negative cases were refractory. Conclusion: LOH at key tumor suppressor genes should be further investigated as predictive for immunotherapy.

KW - FHIT

KW - loss of heterozygosity

KW - renal cell carcinoma

KW - FHIT

KW - loss of heterozygosity

KW - renal cell carcinoma

UR - http://hdl.handle.net/10807/172128

U2 - 10.2217/imt-2017-0160

DO - 10.2217/imt-2017-0160

M3 - Article

SN - 1750-743X

VL - 10

SP - 743

EP - 752

JO - Immunotherapy

JF - Immunotherapy

ER -

Loss of heterozygosity of key tumor suppressor genes in advanced renal cancer patients treated with nivolumab

Abstract

Keywords

OSS delle Nazioni Unite

Accesso al documento

Altri file e collegamenti

Fingerprint

Cita questo